Thermo Fisher’s New Devices, LabGenius, Sanofi Collaboration, Singapore-MIT Alliance Launches New Project
By Bio-IT World Staff
December 22, 2025 | Thermo Fisher Scientific has introduced the Thermo Scientific X and S Series Centrifuges; LabGenius has entered a second collaboration with Sanofi; the Singapore-MIT Alliance for Research and Technology has launched a new collaborative research project; and more.
Researchers at Sanford Burnham Prebys Medical Discovery Institute plan to develop computational models to predict human toxicity thanks to a grant from the Advanced Research Projects Agency for Health (ARPA-H). The multi-institution, $31.7 million contract funds a project called Pharmacological Research and Evaluation through Digital Integration and Clinical Trial Simulation (PREDICTS). In addition to reducing the long timeline usually associated with drug development, the goal is to also reduce the need for laboratory animal models and catch safety problems with new drugs before they are tested in people. Press release.
The Singapore-MIT Alliance for Research and Technology (SMART) launches a new collaborative research project: Wearable Imaging for Transforming Elderly Care (WITEC). WITEC marks a pioneering effort in wearable technology, medical imaging, research, and materials science. It is Singapore’s first center dedicated to foundational research and development of the world’s first wearable ultrasound imaging system capable of 48-hour intermittent cardiovascular imaging for continuous and real-time monitoring and diagnosis of chronic conditions, such as hypertension and heart failure. Press release.
Nanocrine has unveiled its RT-Chip technology, a next-generation biosensor platform that enables real time observation of tumor activity at the cellular level. Nancorine's biochip—initially developed by scientists at the U.S. Naval Research Laboratory—was advanced by collaborations with scientists at the National Institutes of Health and the Frederick Innovative Tech Center. The imaging platform will enable researchers and clinicians to diagnose cancer more quickly and accurately by uncovering the tumors spread at the molecular level, map drug responses in real time on a cellular level that traditional assays miss, and more. Press release.
Thermo Fisher Scientific introduces the Thermo Scientific X and S Series Centrifuges, general purpose centrifuges that combine performance, versatility, and enhanced sustainability to meet current laboratory needs. These 4-liter centrifuges feature natural refrigerant cooling systems are compliant with European Union and U.S. Environmental Protection Agency F-gas regulations. The Thermo Scientific GreenCool Technology utilizes hydrocarbon cooling (R290) with a Global Warming Potential (GWP) of 3, an immense reduction compared to previous cooling systems with a GWP of 1,430. Press release.
LabGenius has entered a second collaboration with Sanofi. This collaboration combines LabGenius’ AI/ML-driven antibody design capabilities with Sanofi’s expertise in the development of therapeutic NANOBODY molecules to co-optimize proteins for therapeutically valuable properties. Following the success of their first collaboration, LabGenius will apply the EVA platform to optimize NANOBODY molecules for multiple new targets in the area of inflammation. Press release.
Pangaea announces a multi‑year strategic collaboration with AstraZeneca to make AI-driven clinical decision-making available at scale, and improve how patients are identified, diagnosed, treated, and connected to existing therapies and clinical trials. As part of the collaboration, AstraZeneca and Pangaea will co‑develop an enterprise‑grade platform that fuses large‑scale clinical, imaging, genomic, pathology, and real‑world data using the latest breakthroughs in generative and predictive AI from Microsoft. Press release.
Inductive Bio has received an up to $21 million award to lead a project to develop next-generation models of drug toxicity to advance safer therapeutics and reduce reliance on animal testing. The company has teamed up with Amgen, Cincinnati Children's Hospital Medical Center, Baylor College of Medicine, and Torch Bio (a University of Michigan Medical School spinout company) to use AI trained on data from advanced human model systems to build toxicity prediction models that could fundamentally change how drug safety is assessed. This approach has the potential to reduce late-stage development failures by leveraging human biology-based predictive models and to ultimately accelerate the delivery of safe, innovative medicines to patients. Press release.
Revvity introduces its forthcoming Signals Xynthetica Models-as-a Service (MaaS) AI offering within the Revvity Signals platform. The Signals Xynthetica offering will enable AI-augmented molecular and materials design, as well as bring together advanced in‑silico generation, predictive modeling, and experimental validation within a single, governed environment that allows scientific teams to iteratively design, test, and refine candidate molecules with increasing confidence. The Signals Xynthetica platform will support a wide range of in-silico design approaches, including de novo generation, property prediction, and multi-objective optimization. Press release.
Harbour BioMed announced a multi-year, global strategic collaboration and license agreement with Bristol Myers Squibb to discover and develop next-generation multi-specific antibodies. Under the terms of the agreement, Harbour BioMed will collaborate with Bristol Myers Squibb to advance and accelerate multi-specific antibody discovery programs. In return, Harbour BioMed could receive payments totaling $90 million, as well as development and commercial milestones of up to $1.035 billion, along with tiered royalties should Bristol Myers Squibb elect to advance all potential programs. Press release.
Galux has signed a research agreement with Boehringer Ingelheim to jointly explore the application of artificial intelligence (AI) in precision protein design for therapeutic development. The goal is to evaluate how AI can be leveraged to design purpose-specific protein molecules that meet precise scientific and translational needs, where conventional approaches face limitations. Press release.
Cytiva and Fida Biosystems have joined forces to expand analytical capabilities for protein research. The collaboration combines Cytiva’s Biacore surface plasmon resonance systems with Fidabio’s in-solution Flow-Induced Dispersion Analysis technology, providing both a complementary and an orthogonal approach that gives scientists a more complete picture of molecular interactions. By linking structural details—such as protein size and stability—with precise binding and interaction data, researchers can make faster, more confident decisions earlier in development. Press release.
The U.S. National Science Foundation Directorate for Technology, Innovation and Partnerships (NSF TIP) announces the launch of a new initiative designed to launch and scale a new generation of independent research organizations. These organizations will focus on technical challenges and bottlenecks that traditional university and industry labs cannot easily solve on their own. NSF seeks feedback on this initiative through a Request for Information (RFI). Press release.